DE69332576T2 - Glykolisierte Cytokine - Google Patents
Glykolisierte CytokineInfo
- Publication number
- DE69332576T2 DE69332576T2 DE69332576T DE69332576T DE69332576T2 DE 69332576 T2 DE69332576 T2 DE 69332576T2 DE 69332576 T DE69332576 T DE 69332576T DE 69332576 T DE69332576 T DE 69332576T DE 69332576 T2 DE69332576 T2 DE 69332576T2
- Authority
- DE
- Germany
- Prior art keywords
- galactose
- interferon
- cytokine
- modified
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 108
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 108
- 102000014150 Interferons Human genes 0.000 claims description 46
- 108010050904 Interferons Proteins 0.000 claims description 46
- 229940079322 interferon Drugs 0.000 claims description 44
- 108010047761 Interferon-alpha Proteins 0.000 claims description 15
- 102000006992 Interferon-alpha Human genes 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000003147 glycosyl group Chemical group 0.000 claims description 11
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 102000000588 Interleukin-2 Human genes 0.000 claims description 10
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 125000005640 glucopyranosyl group Chemical group 0.000 claims description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 210000004185 liver Anatomy 0.000 abstract description 26
- 238000013508 migration Methods 0.000 abstract description 11
- 230000005012 migration Effects 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 208000019423 liver disease Diseases 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 265
- 239000000243 solution Substances 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 75
- 102100040018 Interferon alpha-2 Human genes 0.000 description 64
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 63
- 229930182830 galactose Natural products 0.000 description 62
- 238000000034 method Methods 0.000 description 60
- 239000000872 buffer Substances 0.000 description 52
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 46
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 42
- 108010078049 Interferon alpha-2 Proteins 0.000 description 41
- 239000008363 phosphate buffer Substances 0.000 description 27
- 239000000126 substance Substances 0.000 description 27
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 25
- 239000005695 Ammonium acetate Substances 0.000 description 25
- 235000019257 ammonium acetate Nutrition 0.000 description 25
- 229940043376 ammonium acetate Drugs 0.000 description 25
- 108090000467 Interferon-beta Proteins 0.000 description 24
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 23
- 108010074328 Interferon-gamma Proteins 0.000 description 23
- 239000007795 chemical reaction product Substances 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- YLQSMBXRBZJCHM-UHFFFAOYSA-N (4-fluorophenyl)-(2-methyl-1h-indol-3-yl)methanone Chemical compound CC=1NC2=CC=CC=C2C=1C(=O)C1=CC=C(F)C=C1 YLQSMBXRBZJCHM-UHFFFAOYSA-N 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 22
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 21
- 102100037850 Interferon gamma Human genes 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 102100026720 Interferon beta Human genes 0.000 description 20
- 230000000840 anti-viral effect Effects 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 238000000035 BCA protein assay Methods 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 16
- 235000019624 protein content Nutrition 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 150000002772 monosaccharides Chemical class 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000002440 hepatic effect Effects 0.000 description 12
- -1 2-amino-2-deoxygalactopyranosyl group Chemical group 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- GGYBJYNRLGNUNZ-SJHCENCUSA-N (2r,3r,4r,5r,6s)-2-(hydroxymethyl)-6-(2-isothiocyanatophenyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1C1=CC=CC=C1N=C=S GGYBJYNRLGNUNZ-SJHCENCUSA-N 0.000 description 6
- 208000005176 Hepatitis C Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 description 5
- 229930182475 S-glycoside Natural products 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 241000711549 Hepacivirus C Species 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960001388 interferon-beta Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 2
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- JIZRUFJGHPIYPS-SRVKXCTJSA-N Cys-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O JIZRUFJGHPIYPS-SRVKXCTJSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 150000002256 galaktoses Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- DSTWKJOBKSMVCV-UWVGGRQHSA-N Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DSTWKJOBKSMVCV-UWVGGRQHSA-N 0.000 description 1
- 244000041517 Etlingera elatior Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JTRONPPAUSSTQI-UHFFFAOYSA-N ethane-1,2-diol;ethanol Chemical compound CCO.OCCO JTRONPPAUSSTQI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 150000008273 hexosamines Chemical class 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25496292 | 1992-09-24 | ||
| JP8892093 | 1993-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69332576D1 DE69332576D1 (de) | 2003-01-30 |
| DE69332576T2 true DE69332576T2 (de) | 2003-11-20 |
Family
ID=26430256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69332576T Expired - Fee Related DE69332576T2 (de) | 1992-09-24 | 1993-09-18 | Glykolisierte Cytokine |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5643564A (https=) |
| EP (1) | EP0589378B1 (https=) |
| KR (1) | KR940007058A (https=) |
| CN (1) | CN1087916A (https=) |
| AT (1) | ATE229981T1 (https=) |
| CA (1) | CA2106821A1 (https=) |
| DE (1) | DE69332576T2 (https=) |
| PH (1) | PH31582A (https=) |
| TW (1) | TW263437B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0770195A (ja) * | 1993-08-23 | 1995-03-14 | Yutaka Mizushima | 糖修飾インターフェロン |
| IL116730A0 (en) * | 1995-01-13 | 1996-05-14 | Amgen Inc | Chemically modified interferon |
| DE69636112T2 (de) * | 1995-08-30 | 2006-12-14 | Toray Industries, Inc. | Verfahren zum testen von myocarditis und cardiomyopathie |
| AUPP660698A0 (en) * | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
| AR078117A1 (es) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
| CN103429226A (zh) * | 2011-03-02 | 2013-12-04 | 森苏林公司 | 囊泡组合物 |
| AU2018300069C1 (en) | 2017-07-11 | 2025-11-20 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| KR20260039812A (ko) | 2019-02-06 | 2026-03-20 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386026A (en) * | 1981-04-20 | 1983-05-31 | Merck & Co., Inc. | Cell-specific glycopeptide ligands |
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| JPS63152393A (ja) * | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
| NL194729C (nl) * | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
| US5162503A (en) * | 1987-05-19 | 1992-11-10 | Hoffmann-La Roche, Inc. | Purification of interleukin-2 by receptor-affinity chromatography |
| US4829690A (en) * | 1987-06-26 | 1989-05-16 | Andros Theodore A | Credit card chain holder |
| JPH01102099A (ja) * | 1987-10-14 | 1989-04-19 | Toray Ind Inc | 生理活性を有する糖タンパク質 |
| JPH01102098A (ja) * | 1987-10-14 | 1989-04-19 | Toray Ind Inc | 糖鎖修飾糖タンパク質 |
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| JPH03106900A (ja) * | 1989-09-20 | 1991-05-07 | Toray Ind Inc | 糖鎖修飾ヒトインターフェロン集合体 |
| JPH085914B2 (ja) * | 1990-02-16 | 1996-01-24 | 株式会社ディ・ディ・エス研究所 | グリコシル−蛋白誘導体 |
| US5096816A (en) * | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
| JPH0770195A (ja) * | 1993-08-23 | 1995-03-14 | Yutaka Mizushima | 糖修飾インターフェロン |
-
1993
- 1993-09-14 TW TW082107513A patent/TW263437B/zh active
- 1993-09-18 DE DE69332576T patent/DE69332576T2/de not_active Expired - Fee Related
- 1993-09-18 EP EP93115060A patent/EP0589378B1/en not_active Expired - Lifetime
- 1993-09-18 AT AT93115060T patent/ATE229981T1/de not_active IP Right Cessation
- 1993-09-23 PH PH46943A patent/PH31582A/en unknown
- 1993-09-23 CN CN93117879A patent/CN1087916A/zh active Pending
- 1993-09-23 CA CA002106821A patent/CA2106821A1/en not_active Abandoned
- 1993-09-24 KR KR1019930019661A patent/KR940007058A/ko not_active Withdrawn
-
1995
- 1995-05-31 US US08/455,661 patent/US5643564A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR940007058A (ko) | 1994-04-26 |
| TW263437B (https=) | 1995-11-21 |
| ATE229981T1 (de) | 2003-01-15 |
| DE69332576D1 (de) | 2003-01-30 |
| EP0589378B1 (en) | 2002-12-18 |
| EP0589378A2 (en) | 1994-03-30 |
| PH31582A (en) | 1998-11-03 |
| EP0589378A3 (en) | 1995-02-22 |
| CN1087916A (zh) | 1994-06-15 |
| CA2106821A1 (en) | 1994-03-25 |
| US5643564A (en) | 1997-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5723121A (en) | Sugar modified interferon | |
| DE69430251T2 (de) | Verbesserte interferon-polymerkonjugate | |
| DE3520228C2 (de) | Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| DE60011087T2 (de) | Konjugate zwischen erythropoietin und polyethylenglycol | |
| DE69806055T2 (de) | Verbesserte interferon-polymer konjugate | |
| EP1131422B1 (de) | Rekombinante glycoproteine, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung | |
| DE69230789T2 (de) | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten | |
| DE69219782T2 (de) | Verwendung eines thymosins bei der behandlung von hepatitis c | |
| DE68923723T3 (de) | Modifizierter humaner G-CSF. | |
| DE69520088T2 (de) | Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten | |
| DE3855899T2 (de) | Prozess zur gewinnung von mikrobiell produziertem interleukin-2 | |
| DE3751527T2 (de) | Zusammensetzungen zur Modulation der Effekten von TNF und IL-1. | |
| UA79430C2 (en) | Method for the stepwise attachment of polyethylene glycol to polypeptide | |
| DE69127017T2 (de) | Arzneimittel gegen Leberzirrhose | |
| KR930701601A (ko) | O-글리코실화 ifn-알파 | |
| DE3751593T2 (de) | IL-1 beta Derivate und Medikamente. | |
| DE69712036T2 (de) | Neue verabreichung von thrombopoietin | |
| DE69332576T2 (de) | Glykolisierte Cytokine | |
| CH681625A5 (https=) | ||
| EP0529300A1 (de) | Neues rekombinantes Human-IFN-beta, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zubereitungen | |
| DE69331977T2 (de) | Löslicher LDL-Rezeptor, seine Herstellung und Verwendung | |
| EP2217619B1 (de) | Zyklisches, cystein-freies protein | |
| DE3881467T2 (de) | Vasokonstriktor-Peptid. | |
| DE69824358T2 (de) | Peptidfragment von LALF mit antiviraler Wirkung | |
| JPH10513440A (ja) | 化学的に修飾したインターフェロン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP |
|
| 8339 | Ceased/non-payment of the annual fee |